Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Tandem Diabetes Care makes insulin pumps and related diabetes technology for people who need to manage their blood sugar.
Tandem Diabetes Care makes insulin pumps — small computerized devices that people with diabetes wear on their bodies to deliver insulin throughout the day. Instead of giving themselves several shots with a pen or syringe, users fill a cartridge with insulin, attach a tiny tube or pod, and let the pump do the steady dosing. The company's flagship product line is called t:slim, and its newer, smaller pump is the Mobi. Tandem also sells the software and accessories that tie the whole system together.
The real magic is in the software. Tandem's pumps can connect to a continuous glucose monitor, a sensor that reads blood sugar every few minutes, and adjust insulin automatically. That closed-loop setup — sold under the Control-IQ name — acts like a kind of autopilot for blood sugar, reading the sensor and nudging insulin up or down without the user doing math in their head at 2 a.m. People with type 1 diabetes, who make no insulin of their own, are the core customers, though the pumps are also used by some people with type 2 diabetes who need insulin. Tandem sells to individuals, but the money mostly flows through insurance. In the United States, a pump is typically paid for by a health insurer or government program, and Tandem works with distributors and a network of diabetes educators and doctors to get the devices onto patients. The company also has a growing international business, selling in markets like Canada and parts of Europe. Its main rival in the pump market is Insulet, which makes the tubeless Omnipod, alongside older pump makers like Medtronic.
The business has a few obvious tensions. Pumps are durable goods — a patient keeps one for years — so Tandem must keep winning new patients while also selling them supplies. Competition is intense, and the rise of GLP-1 weight-loss drugs has spooked investors who worry about the future of diabetes device spending, even though those drugs don't replace insulin for type 1 patients. Tandem is a company betting that smarter, automatic insulin delivery — not just a better piece of plastic — is what keeps patients loyal.
Saved answer · last researched 15 Nov 2026